Helix BioPharma Corp. announced that it has granted a world-wide exclusive license for v-DOS47, an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2), to its wholly-owned subsidiary, Helix Polska. Helix expects that day-to-day development activities in respect of v-DOS47 will be coordinated by Helix Polska, and Helix expects that Helix Polska will pursue non-dilutive EU grant financing arrangements to advance those development activities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.23 CAD | 0.00% |
|
-2.13% | +9.52% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 41.26M | |
+22.15% | 46.56B | |
+45.04% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- HBP Stock
- News Helix BioPharma Corp.
- Helix Biopharma Corp. Signs License Agreement with Helix Polska to Develop Cancer Therapies in Poland